Loading
A phase 1/2 trial of IBD0333 in advanced solid tumours, run by SUNHO（China）BioPharmaceutical CO., Ltd., now recruiting.
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06292208 by SUNHO（China）BioPharmaceutical CO., Ltd., with 48 participants planned, started 2024-03-09 and due to reach its primary completion in 2029-12-31. Interventions recorded: IBD0333.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SunHo Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SunHo Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SunHo Biopharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/